For such purpose, we analyzed disease-free survival of patients with a precursor T-cell neoplasm exhibiting differential FADD levels, followed by analysis of transcriptomic and clinical data from a cohort of 264 patients. This evidence concerns the gene FADD and T-cell and NK-cell neoplasm.